These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26248838)

  • 1. Surgery versus SABR for resectable non-small-cell lung cancer.
    Opitz I; Rocco G; Brunelli A; Varela G; Massard G; Weder W;
    Lancet Oncol; 2015 Aug; 16(8):e372-3. PubMed ID: 26248838
    [No Abstract]   [Full Text] [Related]  

  • 2. Surgery versus SABR for resectable non-small-cell lung cancer.
    Hamaji M; Groth SS; Sugarbaker DJ; Burt BM
    Lancet Oncol; 2015 Aug; 16(8):e372. PubMed ID: 26248839
    [No Abstract]   [Full Text] [Related]  

  • 3. Surgery versus SABR for resectable non-small-cell lung cancer.
    Zhang L; Tian J; Wang C
    Lancet Oncol; 2015 Aug; 16(8):e371-2. PubMed ID: 26248837
    [No Abstract]   [Full Text] [Related]  

  • 4. Surgery versus SABR for resectable non-small-cell lung cancer.
    Cao C; D'Amico T; Demmy T; Dunning J; Gossot D; Hansen H; He J; Jheon S; Petersen RH; Sihoe A; Swanson S; Walker W; Yan TD;
    Lancet Oncol; 2015 Aug; 16(8):e370-1. PubMed ID: 26248836
    [No Abstract]   [Full Text] [Related]  

  • 5. Surgery versus SABR for resectable non-small-cell lung cancer - Authors' reply.
    Chang JY; Senan S; Smit EF; Roth JA
    Lancet Oncol; 2015 Aug; 16(8):e374-5. PubMed ID: 26248841
    [No Abstract]   [Full Text] [Related]  

  • 6. Surgery versus SABR for resectable non-small-cell lung cancer.
    Dearman C; van As N; Crellin A; Slevin N; Sharma RA
    Lancet Oncol; 2015 Aug; 16(8):e373-4. PubMed ID: 26248840
    [No Abstract]   [Full Text] [Related]  

  • 7. SABR vs surgery for NSCLC in the media.
    Rice D; Sepesi B; Heymach J; Swisher S; Vaporciyan A
    Lancet Oncol; 2015 Sep; 16(9):e422. PubMed ID: 26370343
    [No Abstract]   [Full Text] [Related]  

  • 8. SABR in early operable lung cancer: time for evidence.
    Treasure T; Rintoul RC; Macbeth F
    Lancet Oncol; 2015 Jun; 16(6):597-8. PubMed ID: 25981817
    [No Abstract]   [Full Text] [Related]  

  • 9. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA
    Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer.
    Katz MS; Husain ZA
    Lancet Oncol; 2016 Feb; 17(2):e41-e42. PubMed ID: 26868347
    [No Abstract]   [Full Text] [Related]  

  • 11. Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: Post hoc analysis dressed up as level-1 evidence?
    Meyers BF; Puri V; Broderick SR; Samson P; Keogan K; Crabtree TD
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):468-71. PubMed ID: 26259993
    [No Abstract]   [Full Text] [Related]  

  • 12. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer - Authors' reply.
    Chang JY; Senan S; Smit EF; Roth JA
    Lancet Oncol; 2016 Feb; 17(2):e42-e43. PubMed ID: 26868349
    [No Abstract]   [Full Text] [Related]  

  • 13. [Randomised comparison of stereotactic body radiotherapy versus lobectomy in stage I NSCLC--level I evidence at last?].
    Guckenberger M; Andratschke N
    Strahlenther Onkol; 2015 Dec; 191(12):988-90. PubMed ID: 26459463
    [No Abstract]   [Full Text] [Related]  

  • 14. Do we know bad science when we see it?
    Jones DR
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):472-3. PubMed ID: 26254751
    [No Abstract]   [Full Text] [Related]  

  • 15. Local Therapy for Limited Metastatic Non-Small Cell Lung Cancer: What Are the Options and Is There a Benefit?
    Iyengar P; Lau S; Donington JS; Suh RD
    Am Soc Clin Oncol Educ Book; 2016; 35():e460-7. PubMed ID: 27249754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
    Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
    Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer.
    Owen D; Siva S; Salama JK; Robinson C; Kruser TJ; Giuliani M
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):5-9. PubMed ID: 35964631
    [No Abstract]   [Full Text] [Related]  

  • 18. SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?
    Chen H; Louie AV
    Curr Treat Options Oncol; 2016 Jun; 17(6):27. PubMed ID: 27098533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
    Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
    J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.
    Smith BD; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Shirvani SM
    J Geriatr Oncol; 2015 Jul; 6(4):324-31. PubMed ID: 26094172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.